QUILT-3.088 NANT Pancreatic Cancer Vaccine: Phase II Randomized Trial of the NANT Pancreatic Cancer Vaccine vs. Standard-of-Care as First- Line Treatment for Patients With Metastatic Pancreatic Cancer

NCT03563144 Phase 2 WITHDRAWN

QUILT-3.088 NANT Pancreatic Cancer Vaccine: Phase II Randomized Trial of the NANT Pancreatic Cancer Vaccine vs. Standard-of-Care as First- Line Treatment for Patients with Metastatic Pancreatic Cancer.

Details

Lead sponsor	ImmunityBio, Inc.
Phase	Phase 2
Status	WITHDRAWN
Start date	2018-08
Completion	2022-02-09

Conditions

• Metastatic Pancreatic Cancer

Interventions

• Gemcitabine
• Nab-paclitaxel
• Aldoxorubicin HCl
• ALT-803
• ETBX-011
• ETBX-021
• ETBX-051
• ETBX-061
• GI-4000
• GI-6207

Primary outcomes

• Progression-Free Survival — 12 mths
  Compare the efficacy of the NANT Pancreatic Cancer Vaccine regimen vs standard-of-care (SoC) therapy as first-line treatment for patients with metastatic pancreatic cancer as assessed by progression-free survival (PFS) using RECIST Version 1.1

Countries

United States